Table 4.
Oncologic and functional outcomes in clinical series consisting of patients who underwent RARP after prostate surgery.
| Series | Study population | Transfusion, n | Rectal injury, n | +LN, n | Continence, n | Potency, n | PSM, n | BCR during f/u, n |
|---|---|---|---|---|---|---|---|---|
| Zugor et al. [38] |
80 pts with TURP before RARP versus 80 pts with RARP | 1 versus 0 | 1 versus 0 | 2 versus 0 | 70 versus 73 | 38 versus 58 | 6 versus 4 | NA |
| Martin et al. [36] | 24 pts with previous treatment to the prostate and RARP versus 486 with no previous treatment and RARP | 0 versus 0 | 0 versus 0 | NA | NA | NA | 5 versus 110 | NA |
| Gupta et al. [37] |
18 pts with TURP before RARP versus 8 pts with pT1b CaP and RARP versus 132 pts with RARP | 2 versus 1 versus 9 | 0 versus 0 versus 0 | 0 versus 0 versus 3 | 6/8 versus 5/6 versus 78/85 | 1/5 versus 1/3 versus 20/61 | 4 versus 1 versus 17 | 3 versus 1 versus 9 (P = 0.04) |
| Martinschek et al. [39] | 19 pts with previous TURP and RARP versus 19 pts with previous TURP and RRP | 0 versus 2 (P < 0.001) | 0 versus 0 | NA | NA | NA | 3 versus 3 | NA |
TURP: transurethral resection of the prostate; RARP: robot-assisted radical prostatectomy; CaP: prostate cancer; LN: lymph node; PSM: positive surgical margin; BCR: biochemical recurrence; and NA: not available.